Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Ironwood Pharmaceuticals (IRWD) EBT (2016 - 2025)

Ironwood Pharmaceuticals (IRWD) has disclosed EBT for 16 consecutive years, with -$160.7 million as the latest value for Q4 2025.

  • Quarterly EBT fell 12.3% to -$160.7 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$91.1 million through Dec 2025, up 10.56% year-over-year, with the annual reading at -$91.1 million for FY2025, 10.56% up from the prior year.
  • EBT hit -$160.7 million in Q4 2025 for Ironwood Pharmaceuticals, down from $68.0 million in the prior quarter.
  • In the past five years, EBT ranged from a high of $72.3 million in Q4 2022 to a low of -$1.1 billion in Q2 2023.
  • Historically, EBT has averaged -$34.4 million across 5 years, with a median of $39.1 million in 2021.
  • Biggest five-year swings in EBT: soared 1106.52% in 2021 and later tumbled 2100.97% in 2023.
  • Year by year, EBT stood at $46.3 million in 2021, then surged by 56.23% to $72.3 million in 2022, then crashed by 57.99% to $30.4 million in 2023, then tumbled by 571.33% to -$143.1 million in 2024, then decreased by 12.3% to -$160.7 million in 2025.
  • Business Quant data shows EBT for IRWD at -$160.7 million in Q4 2025, $68.0 million in Q3 2025, and $37.8 million in Q2 2025.